Peritoneal Carcinosis Clinical Trial
— IPOXAOfficial title:
IPOXA, Phase I/II Dose Escalation Trial Aiming to Evaluate the Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal Carcinosis of Colorectal Origin and Uncertain Resectability.
Peritoneal carcinosis (PC) corresponds to a locoregional extension into the peritoneum of
rare primary peritoneal cancers, or more frequently distant extension of digestive cancers
(colorectal or gastric) or gynecological (ovarian, fallopian tube, or endometrial). PC can be
considered as a distinct oncological entity as its genesis, natural history, and response to
systematic treatments differ to those of other metastases. The development of PC, observed in
25-35% of colorectal cancers, is generally considered as a unfavorable event in the course of
the disease. The prognosis is defined by the possibility of complete resection, possibly
after neoadjuvant treatment. The benefit provided by the combination of cytoreductive surgery
and heated intraperitoneal chemotherapy (HIPEC) with respect to systemic chemotherapy in
patients with PC of colorectal origin has been demonstrated based on overall survival in
several randomized trials, among which one evaluated oxaliplatin. The evaluation of the
clinical benefit-risk related to the repeated administration of non-hyperthermic
intraperitoneal chemotherapy, as has been validated in ovarian cancer, in patients with PC of
colorectal origin is already being investigated by several international teams.
The FOLFOXIRI + bevacizumab every 2 weeks is a modern therapeutic option in patients with
this disease. The intraperitoneal rather than intravenous (IV) administration of oxaliplatin,
in this combination, could increase the response of peritoneal lesions known to be relatively
insensitive to IV chemotherapy.
| Status | Recruiting |
| Enrollment | 47 |
| Est. completion date | March 2019 |
| Est. primary completion date | March 2019 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - =18 years old and = 75 years old - ECOG Performance Status (PS) 0-2 - Peritoneal carcinosis with locoregional extension or metastases of colorectal origin and uncertain resectability - PCI > 20 and / or infiltration of the hepatic pedicle and / or necessary digestive tract resections - Systemic chemotherapy indication, compatible with the FOLFIRI + bevacizumab combination - Satisfactory haematological evaluation: PNN rate greater than 1500 / mm3, platelet count greater than 100 G / l; - Satisfactory renal and hepatic function : serum creatinine =1.5 times the normal lower values or creatinine clearance =50 ml / min, bilirubin =1.25 times lower normal values, AST / ALT =1.5 times the lower normal values (=5 times the lower normal values for patients with liver metastases) - No unstable conditions: myocardial infarction within 6 months prior to the start of the study, congestive heart failure, unstable angina, active cardiomyopathy, unstable rhythm disorder, uncontrolled hypertension, uncontrolled psychiatric disorders, severe infection, peptic ulcer or any condition that could be aggravated by treatment or limit compliance (investigator assessment); - No limitation in the number of previous treatments; - Patients may have received conventional cytotoxic chemotherapy , hormonal or immunological targeted biological agents. They should have recovered from previous grade =2 toxicities - Written informed consent - Known RAS status. Exclusion Criteria: - Extraperitoneal metastases for which the site or number preclude potentially curative surgery at any moment during the course of the disease - Sign of bowel obstruction or lesions whose topography indicates a risk of intestinal perforation or inflammatory bowel disease - ECOG PS 3-4 - Contraindication to the placement of a intraperitoneal central line - Contraindication specifically related to intraperitoneal administration of oxaliplatin - known history of hypersensitivity to oxaliplatin or to the excipients - peripheral sensory neuropathy grade =2 - Pregnant or lactating women - Unable to give consent - Patient under legal protection measures - Refusal to participate in the study |
| Country | Name | City | State |
|---|---|---|---|
| France | CHU Estaing | Clermont-Ferrand | |
| France | Service de Chirurgie Digestive et de l'Urgence, CHU Albert Michallon | Grenoble | |
| France | Département de Chirurgie Cancérologique, Centre Léon Bérard | Lyon | |
| France | Service d'Oncologie Médicale, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud | Pierre-Bénite | |
| France | Service de Chirurgie Digestive et Cancérologique, CHU NORD | Saint-Étienne | |
| France | Service Oncologie Médicale, INSTITUT DE CANCEROLOGIE DE LA LOIRE (ICL) | Saint-Priest-en-Jarez |
| Lead Sponsor | Collaborator |
|---|---|
| Hospices Civils de Lyon |
France,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Adverse events (NCI CTCAE v4.0) | The safety of intraperitoneal (IP) administration of oxaliplatin in combination with systemic chemotherapy FOLFIRI + bevacizumab will be evaluated during the first cycle of therapy according to NCI CTCAE version 4.0 | up to 14 days | |
| Primary | Dose Limiting Toxicities, DLT | The safety of intraperitoneal (IP) administration of oxaliplatin in combination with systemic chemotherapy FOLFIRI + bevacizumab will be evaluated during the first cycle of therapy according to Dose Limiting Toxicities | up to 14 days | |
| Secondary | Overall response rate according to RECIST | Clinical efficacy of intraperitoneal (IP) administration of oxaliplatin in combination with systemic FOLFIRI + bevacizumab assessed by the overall response rate according to RECIST version 1.1 criteria assessed by imaging (TAP scanner and / or MRI if contraindication) performed after 4 cycles, and / or after 8 cycles | up to 4 months | |
| Secondary | Peritoneal Cancer Index (PCI) | Clinical efficacy of intraperitoneal (IP) administration of oxaliplatin in combination with systemic FOLFIRI + bevacizumab assessed by Peritoneal Cancer Index (PCI) performed after 4 cycles, and / or after 8 cycles | up to 4 months | |
| Secondary | Adverse events (NCI CTCAE v4.0) | The safety of intraperitoneal (IP) administration of oxaliplatin in combination with systemic chemotherapy FOLFIRI + bevacizumab will be evaluated throughout the duration of treatment (4 months) and until the end of patient follow up (1 month after treatment discontinuation) according to NCI CTCAE version 4.0 | up to 5 months | |
| Secondary | The quality of life (EORTC QLQ-C30) | The quality of life will be evaluated throughout the duration of treatment (4 months max) after the end of cycle 2, 4, 6 and 8 of chemotherapy according to EORTC QLQ-C30 . | up to 4 months | |
| Secondary | The quality of life (EORTC QLQ-C29) | The quality of life will be evaluated throughout the duration of treatment (4 months max) after the end of cycle 2, 4, 6 and 8 of chemotherapy according to EORTC QLQ-C29. | up to 4 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04221464 -
Development of a Clinical and Biological Database in Peritoneal Carcinosis (BCB CARCINOSE)
|
N/A |